NCT04922658 2024-07-31
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Unknown
Clinical Trials
23 trialsNCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT06255262 2024-02-13
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
China Medical University, China
Phase 1/2 Unknown
NCT06134193 2023-11-18
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04653480 2023-07-17
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
Phase 2 Unknown
NCT05106777 2023-04-12
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT05746728 2023-04-06
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Tongji Hospital
Phase 1/2 Unknown
NCT05747729 2023-02-28
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04996771 2022-11-14
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT05003037 2022-11-04
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05186545 2022-09-02
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05171439 2022-04-14
Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05282433 2022-03-16
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Zhongnan Hospital
Phase 2 Unknown
NCT05056116 2021-12-27
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase NA Unknown
NCT04764006 2021-11-04
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
Fujian Cancer Hospital
Phase 2 Unknown
NCT05030246 2021-09-01
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
Peking University
Phase 2 Unknown
NCT04929652 2021-06-18
Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 1/2 Unknown
NCT04910854 2021-06-02
Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT04524884 2020-08-24
Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
Fudan University
Phase 2 Unknown
NCT03873532 2020-02-13
A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
Hutchmed
Phase 2/3 Unknown
NCT03879057 2019-10-01
Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors
Peking University
Phase 1 Unknown